GlassScriptPhysician profile
Rohit Singhania
NPI 1457664500
$43,664.63
in general payments reported to CMS, 2019-2025
34 companies · $7,441 in 2025
The $7,441 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,709 · 2020: $1,658 · 2021: $2,689 · 2022: $2,904 · 2023: $2,741 · 2024: $24K · 2025: $7,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $10K · Travel and Lodging: $3,278 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,250.00 |
| Food and Beverage | $10,038.01 |
| Travel and Lodging | $3,277.61 |
| Education | $138.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $25,237.59 | 2024-2025 | Voquezna |
| Abbvie INC. | $6,416.43 | 2021-2025 | Linzess, Skyrizi, Rinvoq |
| Ferring International Pharmascience Center US | $2,400.00 | 2019 | |
| Janssen Research & Development, LLC | $1,657.95 | 2020 | |
| Janssen Biotech, INC. | $1,386.38 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,359.69 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,089.76 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $701.31 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $417.60 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $400.16 | 2022-2025 | |
| Pfizer INC. | $299.25 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $243.58 | 2022-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $235.94 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $180.58 | 2024-2025 | |
| Genzyme Corporation | $179.21 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $123.74 | 2022 | |
| Amgen INC. | $120.98 | 2025 | |
| Janssen Scientific Affairs, LLC | $117.34 | 2023 | Stelara |
| Qol Medical, LLC | $110.96 | 2023-2024 | Sucraid, Sucraid |
| Echosens North America, INC. | $108.85 | 2024-2025 | Fibroscan, Fibroscan |
| Exact Sciences Corporation | $102.32 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $100.70 | 2023-2024 | Ibsrela |
| Celltrion USA INC. | $95.28 | 2024-2025 | Vegzelma, Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $94.98 | 2022 | |
| Boston Scientific Corporation | $94.97 | 2022 | |
| Madrigal Pharmaceuticals | $83.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.45 | 2023 | Cyltezo |
| Genentech, INC. | $63.81 | 2019 | |
| Nestle Healthcare Nutrition INC. | $58.09 | 2022-2023 | |
| Cook Medical LLC | $47.66 | 2023 | Fusion |
| Olympus America INC. | $20.58 | 2023 | Single Use Electrosurgical Snare Sd-400 |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Braintree Laboratories, INC. | $15.81 | 2025 | Suflave, Sutab |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Singhania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.